Samchundang Pharm Decides to Dispose of Treasury Stock Worth 29.5 Billion Won! What’s the Investment Strategy? Samchundang Pharm’s announcement of treasury stock disposal is drawing attention from investors. Is this decision good news or bad news? This article closely analyzes the background and impact of the treasury stock disposal and presents key points investors should … Read more
Samchundang Pharm’s ₩29.5 Billion Convertible Bond Issuance: Why You Should Read This Biosimilar company Samchundang Pharm’s decision to issue ₩29.5 billion in convertible bonds is a significant event for investors. Does it signal a positive step towards securing R&D funding or a concerning increase in financial burden? This article provides a comprehensive analysis of the … Read more
Samchundang Pharm CEO’s surprise stock gift: Is it a simple transfer or a sign of something more? This analysis delves into the reasoning behind the gift, the company’s weak Q1 performance, its biosimilar market entry strategy, and other crucial factors for investors. What Happened? On July 24, 2025, Samchundang Pharm’s CEO, Yoon Dae-in, gifted a … Read more